An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer
Metadatos
Mostrar el registro completo del ítemAutor
Morales Santana, Sonia; Morell, Santiago; León, Josefa; Carazo Gallego, Ángel; Jiménez-López, José Carlos; Morell, MaríaEditorial
Frontiers Media
Materia
polymorphism circadian clock genes endocrine cancer
Fecha
2019-02-26Referencia bibliográfica
Morales Santana, S. et. al. Front. Endocrinol. 10:104. [https://doi.org/10.3389/fendo.2019.00104]
Patrocinador
SEIOMM (2017) and SEEN (2018); Ramon y Cajal Research Program from the Spanish Ministry of Economy, Industry and Competitiveness (grant ref. number YC-2014-16536); Grant ref. BFU2016-77243-P; CSIC—intramural grant ref. 201540E065; EU Marie Curie Research Program FP7-PEOPLE-2011-IOF, grant ref. PIOF-GA-2011-301550Resumen
A major consequence of the world industrialized lifestyle is the increasing period of
unnatural light in environments during the day and artificial lighting at night. This major
change disrupts endogenous homeostasis with external circadian cues, which has
been associated to higher risk of diseases affecting human health, mainly cancer
among others. Circadian disruption promotes tumor development and accelerate its
fast progression. The dysregulation mechanisms of circadian genes is greatly affected
by the genetic variability of these genes. To date, several core circadian genes, also
called circadian clock genes, have been identified, comprising the following: ARNTL,
CLOCK, CRY1, CRY2, CSNK1E, NPAS2, NR1D1, NR1D2, PER1, PER2, PER3, RORA,
and TIMELESS. The polymorphic variants of these circadian genes might contribute
to an individual’s risk to cancer. In this short review, we focused on clock circadian
clock-related genes, major contributors of the susceptibility to endocrine-dependent
cancers through affecting circadian clock, most likely affecting hormonal regulation.
We examined polymorphisms affecting breast, prostate and ovarian carcinogenesis,
in addition to pancreatic and thyroid cancer. Further study of the genetic composition
in circadian clock-controlled tumors will be of great importance by establishing the
foundation to discover novel genetic biomarkers for cancer prevention, prognosis and
target therapies.